Search Result

Results for "

demyelinating

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Endogenous Metabolite (3) Integrin (2) Liposome (1) Phosphatase (1) PPAR (1) ROR (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (6)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10216

CAQK peptide	Biochemical Assay Reagents	Neurological Disease
CAQK peptide selectively binds to injured mouse brain. CAQK peptide selectively targets demyelinating areas and it is absent from healthy tissue. The CAQK peptide target is a proteoglycan complex upregulated in brain injuries and is used for drug delivery. CAQK peptide can penetrate the blood-brain barrier .

HY-P1240A

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA 5 Publications Verification MOG (35-55) TFA	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) TFA is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-P1240

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat 5 Publications Verification MOG (35-55)	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat has encephalitogenic activity and induces T?cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-43515

ESI1	Endogenous Metabolite	Metabolic Disease
ESI1 is a small molecule epigenetic silencing inhibitor. ESI1 can trigger the formation of nuclear condensates of key lipid metabolism regulators SREBP1/2, concentrating transcriptional co-activators to drive lipid/cholesterol biosynthesis. ESI1 can promote myelin regeneration in demyelinated animal models and facilitate de novo myelination on regenerating CNS axons, reversing age-related declines in cognitive abilities .

HY-108831

Natalizumab 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-108831A

Natalizumab (Solution) 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-P5982

PTPσ Inhibitor, ISP	Phosphatase	Neurological Disease
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .

HY-115777

ARN-6039	ROR	Neurological Disease
ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease.

HY-107901

Pparδ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
Pparδ agonist 1 is a PPAR-δ agonist, with an EC₅₀ of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.

HY-P10680

TFE-IDAtp1-LinA	Liposome	Others
TFE-IDAtp1-LinA is a highly potent amphiphilic carrier, containing a trifluoroethyl-iminodiacetic acid analog of Stp. TFE-IDAtp1-LinA, formed nanoparticles with Cas9 RNP/ssDNA, achieved enhanced green fluorescent protein knockouts with an ED₅₀ of 0.38 nM Cas9/sgRNA ribonucleoproteins (RNP) .

Cat. No.	Product Name	Target	Research Area

HY-P10216

CAQK peptide	Biochemical Assay Reagents	Neurological Disease
CAQK peptide selectively binds to injured mouse brain. CAQK peptide selectively targets demyelinating areas and it is absent from healthy tissue. The CAQK peptide target is a proteoglycan complex upregulated in brain injuries and is used for drug delivery. CAQK peptide can penetrate the blood-brain barrier .

HY-P1240A

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA 5 Publications Verification MOG (35-55) TFA	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) TFA is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-P1240

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat 5 Publications Verification MOG (35-55)	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat has encephalitogenic activity and induces T?cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-P1240B

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate 5 Publications Verification MOG (35-55) acetate	Peptides	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) acetate is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate has encephalitogenic activity and induces T?cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-P10441A

S-palm P0(180–199) TFA 1 Publications Verification	Peptides	Inflammation/Immunology
S-palm P0(180–199) (TFA) is a peptide that enhances MHC II-restricted responses. S-palm P0(180–199) (TFA) can be used to establish models of chronic inflammatory demyelinating polyneuropathy (CIDP) and chronic experimental autoimmune neuritis (c-EAN). S-palm P0(180–199) (TFA) is used for studying autoimmune-mediated neuroinflammatory diseases .

HY-P5982

PTPσ Inhibitor, ISP	Phosphatase	Neurological Disease
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .

HY-P10441

S-palm P0(180–199)	Peptides	Inflammation/Immunology
S-palm P0(180-199) is a polypeptide that increases MHC Class II limiting reactions. S-palm P0(180-199) can be used to establish a model of chronic inflammatory demyelinating multiple radiculopathy (CIDP) .

HY-P5462

PLP (180-199)	Peptides	Inflammation/Immunology
PLP (180-199) is a biological active peptide. (This is amino acids 180-199 fragment of myelin proteolipid protein (PLP). PLP, the most abundant myelin protein of the central nervous system, has been used in multiple sclerosis (MS) studies. MS is a chronic inflammatory demyelinating disease of the CNS.)

HY-P10680

TFE-IDAtp1-LinA	Liposome	Others
TFE-IDAtp1-LinA is a highly potent amphiphilic carrier, containing a trifluoroethyl-iminodiacetic acid analog of Stp. TFE-IDAtp1-LinA, formed nanoparticles with Cas9 RNP/ssDNA, achieved enhanced green fluorescent protein knockouts with an ED₅₀ of 0.38 nM Cas9/sgRNA ribonucleoproteins (RNP) .

Cat. No.	Product Name	Target	Research Area

HY-108831

Natalizumab 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-108831A

Natalizumab (Solution) 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

Cat. No.	Product Name		Classification

HY-P10680

TFE-IDAtp1-LinA		Azide
TFE-IDAtp1-LinA is a highly potent amphiphilic carrier, containing a trifluoroethyl-iminodiacetic acid analog of Stp. TFE-IDAtp1-LinA, formed nanoparticles with Cas9 RNP/ssDNA, achieved enhanced green fluorescent protein knockouts with an ED₅₀ of 0.38 nM Cas9/sgRNA ribonucleoproteins (RNP) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.